t
On 26 October 2026, Beximco Pharmaceuticals PLC announced that board members Mr. A B Siddiqur Rahman and Ms. Reem H. Shamsuddoha have left the Board with immediate effect. This follows an earlier announcement made by the company on 30 September 2026 regarding board changes. The company stated that it expects to make further announcements regarding additional board changes in due course.
| Date | 26 Oct 2026 |
| Time | 07:49:59 |
| Category | Board changes |
| ID | 4106A |
26 October 2026
BEXIMCO PHARMACEUTICALS PLC.
Board changes
Beximco Pharmaceuticals PLC. ("the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that, further to its announcement on 30 September 2026, the Company can confirm that Mr. A B Siddiqur Rahman and Ms. Reem H. Shamsuddoha have left the Board with immediate effect.
The Company expects to make further announcements, in respect of further board changes, as outlined in the Company's earlier announcement, dated 30 September 2026, in due course.
For further information please visit www.beximcopharma.com or enquire to:
|
Beximco Pharma |
|
Mohammad Ali Nawaz, Chief Financial Officer Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS Executive Director & Company Secretary Tel: +880 2 41060531, Ext. 10140
|
|
SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555
|
|
SP Angel Corporate Finance LLP (Broker) Matthew Johnson Tel: +44 (0) 20 3470 0470
|
|
FTI Consulting Simon Conway / Sam Purewal / Lucy Molloy Tel: +44 (0)20 3727 1000
|
Notes to Editors
About Beximco Pharmaceuticals PLC
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.